Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Hepatocellular carcinoma surveillance and management
Essential points for quick revision.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
HCC is usually managed through an expedited specialist pathway rather than the emergency department, but tumour rupture with sudden abdominal pain, shock or haemoperitoneum is life-threatening. Acute jaundice with sepsis, variceal bleeding, encephalopathy or new decompensation also requires immediate stabilisation through the relevant pathway. Contact hepatobiliary and interventional radiology teams urgently for suspected rupture; do not perform an unplanned percutaneous biopsy in an unstable patient or delay resuscitation for cancer staging.
Synopsis
Deliver purposeful six-monthly surveillance, investigate suspicious lesions correctly, and match hepatocellular carcinoma treatment to tumour burden, liver reserve, performance and transplant potential.
Offer eligible adults with cirrhosis ultrasound surveillance every six months, with or without AFP, when early detection could lead to meaningful treatment.
Chronic hepatitis B can confer HCC risk without cirrhosis, so use the NICE hepatitis B risk-based surveillance recommendations alongside the cirrhosis pathway.
AFP alone is neither sensitive nor specific enough to replace imaging, and a normal value cannot reassure after a suspicious scan.
Key red flags
New decompensation
Worsening ascites, jaundice, encephalopathy or variceal bleeding can reflect tumour progression, portal-vein involvement or unrelated cirrhotic decline and requires expedited reassessment.
Investigation priorities
01
Six-monthly liver ultrasoundFirst step
Detect early focal liver cancer in eligible high-risk people before symptoms develop.
Management branches
SurveilRun a reliable programme
An adult has cirrhosis or another guideline-defined HCC risk and would be eligible for treatment if early cancer were found.
Explain the purpose and limits of surveillance, arrange ultrasound every six months with or without AFP according to the relevant NICE pathway, and record a dependable recall owner.
At each episode, document technical adequacy and reconsider whether health status still permits meaningful HCC treatment, discussing any proposal to stop surveillance with the person.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.